Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Bogdanov MB and Chernen'kaia TV | [Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract]. | 2000 | Antibiot. Khimioter. | pmid:11212394 |
Budanov SV | [Azithromycin (sumamed)--basic properties and therapy of community-acquired pneumonia]. | 2000 | Antibiot. Khimioter. | pmid:11212397 |
Solomon AW et al. | Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana. | 2001 | Bull. World Health Organ. | pmid:11217675 |
Bregani ER et al. | Azithromycin in the treatment of Plasmodium falciparum gametocytes. Preliminary observation. | 2000 | Panminerva Med | pmid:11218625 |
Mizen L | The activity of antibiotics against Legionella pneumophila: in vitro and in vivo studies. | 2001 | J. Antimicrob. Chemother. | pmid:11222573 |
Weiss LM et al. | The treatment of babesiosis. | 2001 | N. Engl. J. Med. | pmid:11236789 |
Ranque S | The treatment of babesiosis. | 2001 | N. Engl. J. Med. | pmid:11236790 |
Dagan R et al. | Antibiotic treatment in acute Otitis Media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment. | 2001 | J. Infect. Dis. | pmid:11237804 |
Hyde TB et al. | Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia. | 2001 | J. Infect. Dis. | pmid:11237807 |
Cascaval RI and Lancaster DJ | Hypersensitivity syndrome associated with azithromycin. | 2001 | Am. J. Med. | pmid:11247598 |
Duran JM and Amsden GW | Azithromycin: indications for the future? | 2000 | Expert Opin Pharmacother | pmid:11249533 |
Amábile-Cuevas CF et al. | Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. | 2001 | Clin. Infect. Dis. | pmid:11249826 |
De Diego JI et al. | Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. | 2001 | Int. J. Pediatr. Otorhinolaryngol. | pmid:11249979 |
Sahm DF et al. | Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. | 2001 | Antimicrob. Agents Chemother. | pmid:11257013 |
Baumann U et al. | Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. | 2001 Jan-Feb | Infection | pmid:11261763 |
Lietman T and Fry A | Can we eliminate trachoma? | 2001 | Br J Ophthalmol | pmid:11264123 |
Grand A et al. | [Subacute infectious endocarditis due to the agent of cat scratch fever: Bartonella henselae]. | 2001 | Arch Mal Coeur Vaiss | pmid:11265556 |
Graybill JR and Bocanegra R | Treatment alternatives for Mycobacterium kansasii. | 2001 | J. Antimicrob. Chemother. | pmid:11266413 |
Ferwerda A et al. | Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. | 2001 | J. Antimicrob. Chemother. | pmid:11266417 |
Butler T et al. | In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. | 2001 | J. Antimicrob. Chemother. | pmid:11266420 |